Guardant Health, Inc. announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study. This study evaluates emerging multi-cancer detection (MCD) technology, with Guardant’s Shield MCD test selected for use.
The four-year study aims to enroll up to 24,000 patients aged 45-75 who do not currently have cancer, evaluating the use of MCD tests in future randomized controlled trials. The Shield MCD test was chosen based on its performance in detecting 10 cancer types.
Craig Eagle, MD, Guardant Health Global Chief Medical Officer, stated that new screening technology like the Shield MCD test has the potential to detect multiple cancers earlier through a simple blood draw. This study is a critical step in evaluating the role of this breakthrough technology in reducing cancer deaths.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.